HC Wainwright & Co. Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and a price target of $22.
June 06, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Lexeo Therapeutics with a Buy rating and a price target of $22, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $22 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100